Literature DB >> 25379860

The impact of neural invasion severity in gastrointestinal malignancies: a clinicopathological study.

Florian Liebl1, Ihsan Ekin Demir, Katharina Mayer, Tibor Schuster, Jan G DʼHaese, Karen Becker, Rupert Langer, Frank Bergmann, Kun Wang, Robert Rosenberg, Alexander R Novotny, Marcus Feith, Daniel Reim, Helmut Friess, Güralp O Ceyhan.   

Abstract

OBJECTIVES: Because neural invasion (NI) is still inconsistently reported and not well characterized within gastrointestinal malignancies (GIMs), our aim was to determine the exact prevalence and severity of NI and to elucidate the true impact of NI on patient's prognosis.
BACKGROUND: The union internationale contre le cancer (UICC) recently added NI as a novel parameter in the current TNM classification. However, there are only a few existing studies with specific focus on NI, so that the distinct role of NI in GIMs is still uncertain.
MATERIALS AND METHODS: NI was characterized in approximately 16,000 hematoxylin and eosin tissue sections from 2050 patients with adenocarcinoma of the esophagogastric junction (AEG)-I-III, squamous cell carcinoma (SCC) of the esophagus, gastric cancer (GC), colon cancer (CC), rectal cancer (RC), cholangiocellular cancer (CCC), hepatocellular cancer (HCC), and pancreatic cancer (PC). NI prevalence and severity was determined and related to patient's prognosis and survival.
RESULTS: NI prevalence largely varied between HCC/6%, CC/28%, RC/34%, AEG-I/36% and AEG-II/36%, SCC/37%, GC/38%, CCC/58%, and AEG-III/65% to PC/100%. NI severity score was uppermost in PC (24.9±1.9) and lowest in AEG-I (0.8±0.3). Multivariable analyses including age, sex, TNM stage, and grading revealed that the prevalence of NI was significantly associated with diminished survival in AEG-II/III, GC, and RC. However, increasing NI severity impaired survival in AEG-II/III and PC only.
CONCLUSIONS: NI prevalence and NI severity strongly vary within GIMs. Determination of NI severity in GIMs is a more precise tool than solely recording the presence of NI and revealed dismal prognostic impact on patients with AEG-II/III and PC. Evidently, NI is not a concomitant side feature in GIMs and, therefore, deserves special attention for improved patient stratification and individualized therapy after surgery.

Entities:  

Mesh:

Year:  2014        PMID: 25379860     DOI: 10.1097/SLA.0000000000000968

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  29 in total

1.  Presence of cancer cells in the periarterial tissues of patients with advanced gastric cancer.

Authors:  Hiroshi Yamamoto; Satoshi Murata; Sachiko Kaida; Tsuyoshi Yamaguchi; Mitsuaki Ishida; Ryoji Kushima; Masaji Tani
Journal:  Oncol Lett       Date:  2018-05-11       Impact factor: 2.967

2.  Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma.

Authors:  M Amit; S Na'ara; L Leider-Trejo; Y Binenbaum; N Kulish; E Fridman; A Shabtai-Orbach; R J Wong; Z Gil
Journal:  Oncogene       Date:  2017-01-16       Impact factor: 9.867

Review 3.  Neural plasticity in pancreatitis and pancreatic cancer.

Authors:  Ihsan Ekin Demir; Helmut Friess; Güralp O Ceyhan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-13       Impact factor: 46.802

4.  Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cells.

Authors:  Ihsan Ekin Demir; Kristina Kujundzic; Paulo L Pfitzinger; Ömer Cemil Saricaoglu; Steffen Teller; Timo Kehl; Carmen Mota Reyes; Linda S Ertl; Zhenhua Miao; Thomas J Schall; Elke Tieftrunk; Bernhard Haller; Kalliope Nina Diakopoulos; Magdalena U Kurkowski; Marina Lesina; Achim Krüger; Hana Algül; Helmut Friess; Güralp O Ceyhan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-16       Impact factor: 11.205

5.  Prospective Evaluation of Associations between Cancer-Related Pain and Perineural Invasion in Patients with Resectable Pancreatic Adenocarcinoma.

Authors:  Rosalie A Carr; Alexandra M Roch; Xin Zhong; Eugene P Ceppa; Nicholas J Zyromski; Attila Nakeeb; C Max Schmidt; Michael G House
Journal:  J Gastrointest Surg       Date:  2017-08-07       Impact factor: 3.452

Review 6.  Disorders of the enteric nervous system - a holistic view.

Authors:  Beate Niesler; Stefanie Kuerten; I Ekin Demir; Karl-Herbert Schäfer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-01-29       Impact factor: 46.802

7.  Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma.

Authors:  Ekaterina Petrova; Verena Zielinski; Louisa Bolm; Cleopatra Schreiber; Juliana Knief; Christoph Thorns; Peter Bronsert; Sylvia Timme-Bronsert; Dirk Bausch; Sven Perner; Tobias Keck; Ulrich Wellner
Journal:  Virchows Arch       Date:  2019-11-30       Impact factor: 4.064

8.  β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer.

Authors:  Bernhard W Renz; Ryota Takahashi; Takayuki Tanaka; Marina Macchini; Yoku Hayakawa; Zahra Dantes; H Carlo Maurer; Xiaowei Chen; Zhengyu Jiang; C Benedikt Westphalen; Matthias Ilmer; Giovanni Valenti; Sarajo K Mohanta; Andreas J R Habenicht; Moritz Middelhoff; Timothy Chu; Karan Nagar; Yagnesh Tailor; Riccardo Casadei; Mariacristina Di Marco; Axel Kleespies; Richard A Friedman; Helen Remotti; Maximilian Reichert; Daniel L Worthley; Jens Neumann; Jens Werner; Alina C Iuga; Kenneth P Olive; Timothy C Wang
Journal:  Cancer Cell       Date:  2017-12-14       Impact factor: 31.743

9.  Nerve Growth Factor Expression Is Not Associated with Perineural Invasion in Extrahepatic Cholangiocarcinoma.

Authors:  Kazuhide Urabe; Yoshiaki Murakami; Naru Kondo; Kenichiro Uemura; Yasushi Hashimoto; Naoya Nakagawa; Hayato Sasaki; Eiso Hiyama; Shinya Takahashi; Taijiro Sueda
Journal:  Dig Dis Sci       Date:  2015-11-07       Impact factor: 3.199

10.  Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer.

Authors:  Robert S Banh; Douglas E Biancur; Keisuke Yamamoto; Albert S W Sohn; Beth Walters; Miljan Kuljanin; Ajami Gikandi; Huamin Wang; Joseph D Mancias; Robert J Schneider; Michael E Pacold; Alec C Kimmelman
Journal:  Cell       Date:  2020-11-02       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.